All Events and PresentationsJune 30, 2025Recludix Platform has Unlocked Development of Oral, Reversible Small Molecule Inhibitors of SH2 DomainsView Poster »May 18, 2025Highly selective and reversible STAT6 inhibition demonstrates potential for differentiated efficacy and safety profile in type 2 allergic inflammationView Poster »May 8, 2025Novel Inhibitors of the BTK SH2 Domain Selectively and Potently Block BTK Signaling and are Efficacious in Preclinical Models of Chronic Spontaneous UrticariaView Poster »December 7, 2023STAT6 Program Highlighted in Sanofi R&D DayAccess Webcast »
